Aranscia and Signature RX have partnered for the development of new biomarkers and personalized medication management solutions relating to GLP-1 treatments. GLP-1s are a class of medications indicated for chronic diseases like type 2 diabetes and obesity.
This partnership aims to expand the exploration of the pharmacogenomic parameters in GLP-1 receptor agonists, allowing more individualized and effective medication management and catering to the supply chain requirements of such medications. With the help of AccessDx Laboratory, an Aranscia subsidiary dedicated to developing new companion diagnostics for GLP-1 medications, and YouScript, a pharmacogenomics platform, a personalized program will be implemented to improve patient outcomes and reduce care costs.
Aranscia specializes in diagnostic software and services that enhance precision medicine. The company’s portfolio includes solutions such as YouScript and 2bPrecise, a software suite that integrates genomic data into electronic medical records (EMRs) to assist healthcare providers in making informed decisions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.